Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Needham Keeps 'Strong Buy' on Dendreon


Needham reiterated his strong buy rating for Dendreon (DNDN).

Analyst Mark Monane says data demonstrated Provenge's effect in the hardest-to-achieve clinical outcome (survival), and further validates the previous benefits seen with the vaccine in radiographic (time-to-disease progress), clinical (delay of bone pain onset), and immunological (T-cell proliferation) outcomes.

While Provenge (Phase 3, unpartnered) will likely not reach the market until the first quarter of 2006, he sees many events to stimulate investor interest over the next 6-to-12 months, including the completion of enrollment of another Provenge Phase 3 trial,and a marketing partnership for Provenge. He has a $15 12-month target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus